Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From Coronavirus Disease 2019 in Adults Aged ≥70 Years.

Jamie Lopez BernalNick AndrewsCharlotte GowerJulia StoweElise TessierRuth SimmonsMary Ramsay

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

We estimated the risk of death from coronavirus disease 2019 in vaccinated compared with unvaccinated patients. The risk of death was reduced 44% after 1 dose of the Pfizer-BioNTech BNT162b2 vaccine, 55% after 1 dose of the Oxford-Astrazeneca ChAdOx1 vaccine, and 69% after 2 doses of the BNT162b2 vaccine. This is above the protection provided against infection.

Keyphrases

coronavirus disease
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
sars cov
prognostic factors
respiratory syndrome coronavirus
peritoneal dialysis